Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.54%. A quarter ago, it was expected that this company would post a loss of $1.13 per share when it actually produced a loss of $1.11, delivering a surprise of 1.77%.Over the last four quarters, the company has su ...